K M Jorga1, D J Nicholl. 1. Department of Clinical Pharmacology, F. Hoffmann-La Roche Ltd, Basel, Switzerland. karin.jorga@roche.com
Abstract
AIMS: Tolcapone is a novel catechol-O-methyltransferase (COMT) inhibitor used as an adjunct to levodopa/carbidopa or levodopa/benserazide therapy to improve treatment of Parkinson's disease. The aim of the current study was to investigate the potential effect of tolcapone on the pharmacokinetics of carbidopa. METHODS: This was an open-label study in 12 parkinsonian patients receiving optimal levodopa/carbidopa therapy and tolcapone 200 mg three times daily for 6 weeks. Blood samples were taken at baseline (i.e. before the first tolcapone intake) and after 1-2 weeks and 6 weeks so that carbidopa pharmacokinetics before and during tolcapone treatment could be assessed. RESULTS: No changes in any pharmacokinetic parameters of carbidopa were observed. The mean AUC(0,tau) and Cmax values at baseline were 0.39 microg ml-1 h and 0. 14 microg ml-1, respectively. During tolcapone treatment these values were on average 0.35 microg ml-1 h (AUC(0,tau), week 1-2), 0. 34 microg ml-1 h (AUC(0,tau), week 6 and 0.13 microg ml-1 (Cmax, weeks 1-2 and 6). tmax remained unchanged (approx. 2 h). CONCLUSIONS: These results indicate that tolcapone does not affect carbidopa elimination and that no interaction of any clinical relevance occurs between tolcapone and carbidopa.
AIMS: Tolcapone is a novel catechol-O-methyltransferase (COMT) inhibitor used as an adjunct to levodopa/carbidopa or levodopa/benserazide therapy to improve treatment of Parkinson's disease. The aim of the current study was to investigate the potential effect of tolcapone on the pharmacokinetics of carbidopa. METHODS: This was an open-label study in 12 parkinsonianpatients receiving optimal levodopa/carbidopa therapy and tolcapone 200 mg three times daily for 6 weeks. Blood samples were taken at baseline (i.e. before the first tolcapone intake) and after 1-2 weeks and 6 weeks so that carbidopa pharmacokinetics before and during tolcapone treatment could be assessed. RESULTS: No changes in any pharmacokinetic parameters of carbidopa were observed. The mean AUC(0,tau) and Cmax values at baseline were 0.39 microg ml-1 h and 0. 14 microg ml-1, respectively. During tolcapone treatment these values were on average 0.35 microg ml-1 h (AUC(0,tau), week 1-2), 0. 34 microg ml-1 h (AUC(0,tau), week 6 and 0.13 microg ml-1 (Cmax, weeks 1-2 and 6). tmax remained unchanged (approx. 2 h). CONCLUSIONS: These results indicate that tolcapone does not affect carbidopa elimination and that no interaction of any clinical relevance occurs between tolcapone and carbidopa.
Authors: S Vickers; E K Stuart; J R Bianchine; H B Hucker; M E Jaffe; R E Rhodes; W J Vandenheuvel Journal: Drug Metab Dispos Date: 1974 Jan-Feb Impact factor: 3.922
Authors: M C Kurth; C H Adler; M S Hilaire; C Singer; C Waters; P LeWitt; D A Chernik; E E Dorflinger; K Yoo Journal: Neurology Date: 1997-01 Impact factor: 9.910
Authors: S Ahtila; S Kaakkola; A Gordin; K Korpela; S Heinävaara; M Karlsson; T Wikberg; P Tuomainen; P T Männistö Journal: Clin Neuropharmacol Date: 1995-02 Impact factor: 1.592
Authors: J G Nutt; W R Woodward; R M Beckner; C K Stone; K Berggren; J H Carter; S T Gancher; J P Hammerstad; A Gordin Journal: Neurology Date: 1994-05 Impact factor: 9.910